147060-42-2

Basic information

• Product Name: 4-amino-5-fluoro-1-[(2S,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2(1H)-one
• Synonyms: 2(1H)-pyrimidinone, 4-amino-5-fluoro-1-[(2S,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-
• CAS NO: 147060-42-2
• Molecular Formula: C₈H₁₀FN₃O₄
• Molecular Weight: 231.1811
• Mol File: 147060-42-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 391.2°C at 760 mmHg
• Flash Point: 190.4°C
• Density: 1.81g/cm³
• Vapor Pressure: 9.74E-08mmHg at 25°C
• Refractive Index: 1.671
• CAS DataBase Reference: 4-amino-5-fluoro-1-[(2S,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-5-fluoro-1-[(2S,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2(1H)-one(147060-42-2)
• EPA Substance Registry System: 4-amino-5-fluoro-1-[(2S,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2(1H)-one(147060-42-2)

Safety Data

• Hazardous Substances Data: 147060-42-2(Hazardous Substances Data)

Upstream product

• 307002-00-2 (2R)-2-benzyloxymethyl-4-acetoxy-1,3-dioxolane 
• 192581-99-0 (2S)-2-((benzyloxy)methyl)-1,3-dioxolan-4-yl acetate 
• 146996-30-7 (+)-(2S,4R)-N⁴-benzoyl-1-<2-<(benzoyloxy)methyl>-1,3-dioxolan-4-yl>-5-fluorocytosine 
• 146996-29-4 (+)-(2S,4S)-N⁴-benzoyl-1-<2-<(benzoyloxy)methyl>-1,3-dioxolan-4-yl>-5-fluorocytosine 

Relevant articles and documents

BASE-MODIFIED CYTIDINE NUCLEOTIDES FOR LEUKEMIA THERAPY

Compounds of the formula I wherein X is a bond or -CH2, and pharmaceutically acceptable salts thereof are useful in the parenteral treatment of leukemia, myelodysplastic syndrome or lymphoma, especially in patients presenting with cytarabine re

Synthesis of enantiomerically pure D-FDOC, an anti-HIV agent

The d-enantiomer of FDOC was obtained in optically pure form via a tandem kinetic resolution/chiral salt crystallization protocol. In addition, conditions were developed that allowed the unwanted l-enantiomer to be racemized and recycled. The β-d-enantiomer of FDOC (2′,3′-dideoxy-5-fluoro- oxacytidine) exhibits potent anti-HIV-1 activity. It was obtained in optically pure form by employing a tandem kinetic resolution/chiral salt crystallization protocol. In addition, conditions were developed that allowed the unwanted butyrate ester of the l-enantiomer of FDOC to be racemized. This material could then be recycled in future resolutions.

Structure-activity relationships among a new class of antiviral heterosubstituted 2',3'-dideoxynucleoside analogues

3'-Oxa-4'-thiocytidine nucleoside analogues 14-17 were prepared from oxathiolanes 10 and 11, and evaluated for activity against HIV-1 and HBV in vitro. The nucleoside analogues were found to possess potent activities against HIV-1 in a panel of cell lines. Compound 16 is moderately active against HBV in 2.2.15 cells.